A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study
consisting of a screening period of up to 4 weeks, a 4 week randomized double-blind,
dose-titration treatment period, followed by a 1 week safety follow-up period after the last
dose of study medication, and a scheduled follow-up safety telephone call one week later.